Consolidated revenue KRW 32,148M (+31.1% YoY), operating profit KRW 9,467M, net profit KRW 13,371M (swing from net loss of KRW 1,046M in prior year same period)
Listing eligibility review resolved: listing maintained on Jan 20, 2026, trading resumed
AI endoscopy solution 'INFINITT Smart Endo' granted new health technology assessment deferral (Feb 2026–Jan 2028); digital pathology 'INFINITT DPS' obtained FDA 510(k) clearance
Net gain of KRW 1,824M from fair value changes in overseas listed ETFs
Some subsidiaries (e.g., INFINITT North America) have negative equity but unrecognized cumulative losses monitored
Dividends: Q4 2025 interim and year-end dividends of KRW 100 per share each (total KRW 200 per share)
Risks: corporate tax surcharge of KRW 1,462M (Jul 2025) and designation as an unfaithful disclosure company (8 penalty points, replaced by fine)